These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15650969)

  • 21. Review article: pharmacological treatment of hepatorenal syndrome.
    Ginès P; Torre A; Terra C; Guevara M
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ascites: diagnosis and management.
    Hou W; Sanyal AJ
    Med Clin North Am; 2009 Jul; 93(4):801-17, vii. PubMed ID: 19577115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chinese guidelines on the management of ascites and its related complications in cirrhosis.
    ; Xu X; Duan Z; Ding H; Li W; Jia J; Wei L; Linghu E; Zhuang H
    Hepatol Int; 2019 Jan; 13(1):1-21. PubMed ID: 30656520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy.
    Arroyo V
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():49-54; discussion 55-6. PubMed ID: 15335402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study.
    Choi CH; Ahn SH; Kim DY; Lee SK; Park JY; Chon CY; Moon YM; Han KH
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1215-22. PubMed ID: 16048569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 28. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
    Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ascites, spontaneous bacterial peritonitis and hepatorenal syndrome].
    Gerbes AL; Gülberg V
    Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S237-9. PubMed ID: 16435724
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
    Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of albumin in patients with decompensated cirrhosis: the case in favor.
    Maor Y
    Isr Med Assoc J; 2005 Feb; 7(2):115-8. PubMed ID: 15729966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ascites in cirrhosis: a review of management and complications.
    Kuiper JJ; van Buuren HR; de Man RA
    Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
    Angeli P; Guarda S; Fasolato S; Miola E; Craighero R; Piccolo F; Antona C; Brollo L; Franchin M; Cillo U; Merkel C; Gatta A
    Aliment Pharmacol Ther; 2006 Jan; 23(1):75-84. PubMed ID: 16393283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hepatorenal syndrome: a new therapeutic approach?].
    Gerbes AL; Gülberg V
    Z Gastroenterol; 1999 Sep; 37(9):983-5. PubMed ID: 10522370
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R; Lebrec D
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological treatment of ascites and hepatorenal syndrome].
    Gülberg V; Gerbes AL
    Dtsch Med Wochenschr; 2003 Feb; 128(8):375-7. PubMed ID: 12594623
    [No Abstract]   [Full Text] [Related]  

  • 38. [Consensus document on the treatment of ascites, dilutional hyponatremia and hepatorenal syndrome in liver cirrhosis].
    Ginès P; Cabrera J; Guevara M; Morillas R; Ruiz del Arbol L; Solàe R; Soriano G
    Gastroenterol Hepatol; 2004 Nov; 27(9):535-44. PubMed ID: 15544740
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy].
    Lööf L; Prytz H; Söderlund C; Wallerstedt S
    Lakartidningen; 2001 Dec; 98(49):5649-52, 5655. PubMed ID: 11783052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug insight: the role of albumin in the management of chronic liver disease.
    Wong F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4(1):43-51. PubMed ID: 17203088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.